Autologous Stem Cell Transplant: Benefits & Risks
An autologous stem cell transplant is a medical procedure that involves taking stem cells from the body of a person, processing and storing them, and then reinfusing them back into the same person’s body. This procedure has been used to treat various kinds of illnesses, including blood cancer and other diseases of the immune system. […]
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial Sloan Kettering Cancer Center (MSK). The Phase […]
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an […]
What makes a stem cell a stem cell and how does it go bad?
Dr. John Dick was awarded the Canada Gairdner International Award 2022 “For the discovery and characterization of leukemic stem cells, providing insights into the understanding, diagnosis and treatment of acute myeloid leukemia.” He presented his award-winning research at the 2022 Gairdner Science Week Laureate Lectures.
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]
Global Stem Cells Market to Generate Revenue of $25.68 Billion By 2028 | More than 80% of Revenue Comes from Adult Stem Cells
Westford,USA, Nov. 02, 2022 (GLOBE NEWSWIRE) — The demand for stem cells market is growing rapidly as the potential for their use in medical treatments expands. In particular, there is great interest in using stem cells to treat a range of degenerative diseases and injuries, as well as to improve the success of organ transplants. Recent advances […]
Emulating the heart – Developing blood stem cells to treat cancer
Making stem cells from a patient’s adult cells – rather than human embryos – is one of the holy grails in modern medicine treatments. New research brings us two steps closer. *** All content on NationalStemCellTherapy.com is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.
Bone Marrow Transplant and Cell Therapies Unit at Tampa General Hospital Brings More Treatment Options to Cancer Patients
TAMPA, Fla., Oct. 3, 2022 /PRNewswire/ — As part of its commitment to world-class, innovative cancer care for the Tampa Bay region and beyond, Tampa General Hospital (TGH) Cancer Institute has established an adult Bone Marrow Transplant (BMT) and Cell Therapies unit that focuses on treating patients with aggressive blood cancers such as leukemias, lymphomas, multiple […]
Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML)
MENLO PARK, Calif., July 15, 2022 /PRNewswire/ — Escend Pharmaceuticals, Inc., a privately held company focused on the development of small molecule therapeutics for oncology orphan diseases, announced today that the United States Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for its lead drug candidate, ES-3000 for a Phase I […]
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD33 and CLL-1 in human hematopoietic stem cells (HSCs) demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia (AML). The data […]